A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. In the second quarter, we recognized other income of $637,000 from the sale of our samples related to the licensed product.
| Segment | 2024 | % of Total |
|---|---|---|
Biotechnology Segment | $1M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 29M | - | 17M |
| Net Income | -9.2M | -9.7M | -17M | -2.6M | -64M | -25M |
| EPS | $-3.72 | $-4.75 | $-10.55 | $-2.80 | $-108.50 | $-42.00 |
| Free Cash Flow | 0 | -2.9M | -10M | -36M | -36M | -42M |
| ROIC | -303.6% | -142.7% | -390.9% | -17.3% | -76.2% | -31.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.22 | 2.82 | 0.56 | 1.22 | 0.27 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -9.6M | -12M | -15M | -1.8M | -63M | -25M |
| Operating Margin | 0.0% | - | - | -6.4% | - | -153.1% |
| ROE | -133.2% | -197.9% | -558.0% | -17.3% | -570.7% | -40.1% |
| Shares Outstanding | 6M | 2M | 6M | 1M | 1M | 1M |
EXICURE, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
EXICURE, INC. (XCUR) has a 5-year average return on invested capital (ROIC) of -66.9%. This is below average and may indicate limited pricing power.
EXICURE, INC. (XCUR) has a market capitalization of $25M. It is classified as a small-cap stock.
EXICURE, INC. (XCUR) does not currently pay a regular dividend.
EXICURE, INC. (XCUR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
EXICURE, INC. (XCUR) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
EXICURE, INC. (XCUR) has a debt-to-equity ratio of 1.22. This indicates moderate leverage.
EXICURE, INC. (XCUR) reported earnings per share (EPS) of $-4.75 in its most recent fiscal year.
EXICURE, INC. (XCUR) has a return on equity (ROE) of -197.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for EXICURE, INC. (XCUR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
EXICURE, INC. (XCUR) has a book value per share of $3.32, based on its most recent annual SEC filing.